Why do dht levels increase

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: DHT levels increase primarily due to the conversion of testosterone by the enzyme 5-alpha-reductase, which occurs in tissues like the prostate, skin, and hair follicles. This conversion typically begins during puberty, around ages 9-14 in males, and can be influenced by genetic factors, with studies showing that about 50% of men experience noticeable hair loss by age 50 due to DHT sensitivity. In conditions like benign prostatic hyperplasia (BPH), DHT levels in the prostate can be 5-10 times higher than normal, contributing to prostate enlargement. Additionally, certain medications, hormonal imbalances, or aging can elevate DHT, with levels often peaking in early adulthood and gradually declining after age 30.

Key Facts

DHT is derived from testosterone via the enzyme 5-alpha-reductase, with two main isoforms: type 1 (found in skin and liver) and type 2 (in prostate and hair follicles).
In males, DHT production increases during puberty, typically starting between ages 9-14, and plays a key role in developing male secondary sexual characteristics.
DHT is a major factor in androgenetic alopecia (male pattern baldness), affecting approximately 50% of men by age 50 and 80% by age 80, according to genetic studies.
In benign prostatic hyperplasia (BPH), DHT levels in the prostate can be 5-10 times higher than normal, contributing to prostate enlargement that affects about 50% of men over 50.
Medications like finasteride (approved by the FDA in 1992) and dutasteride can reduce DHT levels by inhibiting 5-alpha-reductase, with finasteride reducing serum DHT by about 70%.

Overview

Dihydrotestosterone (DHT) is a potent androgen hormone derived from testosterone, first identified in the 1960s through research on sexual differentiation. It plays a crucial role in male development, particularly during fetal stages and puberty, influencing the formation of male genitalia and secondary sexual characteristics. Historically, DHT's significance was highlighted in the 1970s when studies linked it to conditions like benign prostatic hyperplasia (BPH) and androgenetic alopecia. For example, in 1974, research by Julianne Imperato-McGinley et al. on genetic 5-alpha-reductase deficiency in the Dominican Republic showed that individuals lacking DHT developed male internal structures but female external genitalia, underscoring DHT's role in masculinization. Today, DHT is a key target in treating hair loss and prostate disorders, with global markets for related medications exceeding $1 billion annually.

How It Works

DHT levels increase through a biochemical process where testosterone is converted by the enzyme 5-alpha-reductase, primarily in tissues like the prostate, skin, and hair follicles. This enzyme has two main isoforms: type 1, found in skin and liver, and type 2, concentrated in the prostate and scalp. The conversion rate is influenced by genetic factors, with variations in the SRD5A2 gene affecting enzyme activity; for instance, certain polymorphisms can increase DHT production by up to 30%. Hormonal triggers, such as puberty or stress, can upregulate 5-alpha-reductase expression, leading to higher DHT synthesis. In conditions like BPH, DHT binds to androgen receptors in prostate cells, stimulating growth and potentially causing enlargement by 20-30% in affected individuals. Medications like finasteride work by inhibiting type 2 5-alpha-reductase, reducing DHT levels by approximately 70% in serum.

Why It Matters

Understanding why DHT levels increase is vital due to its significant health impacts. In dermatology, elevated DHT contributes to androgenetic alopecia, affecting millions worldwide and driving a hair loss treatment market valued at over $3 billion in 2023. In urology, high DHT is linked to BPH, which impacts about 50% of men over 50 and can lead to urinary issues, increasing healthcare costs by an estimated $4 billion annually in the U.S. Additionally, DHT influences conditions like hirsutism in women and prostate cancer risk, with studies suggesting that reducing DHT may lower prostate cancer incidence by up to 25%. This knowledge informs treatments, such as 5-alpha-reductase inhibitors, which improve quality of life for patients and highlight the importance of hormonal balance in aging populations.